RBC Capital Maintains Outperform on Biogen, Raises Price Target to $357
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has maintained an 'Outperform' rating on Biogen (NASDAQ:BIIB) and raised the price target from $354 to $357.
August 29, 2023 | 2:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biogen's price target has been raised from $354 to $357 by RBC Capital, which maintains an 'Outperform' rating on the stock.
The raised price target and maintained 'Outperform' rating by RBC Capital indicates a positive outlook for Biogen. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100